Latest News by Industry
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — FibroGen Inc. (FGEN) on Monday reported a loss of $66.2 million in its fourth quarter.
The San Francisco-based company said it had a loss of 70 cents per share.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 95 cents per share.
The biotech drug developer posted revenue of $34.4 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $23.9 million.
For the year, the company reported that its loss widened to $293.7 million, or $3.14 per share. Revenue was reported as $140.7 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a FGEN">Zacks stock report on FGEN at https://www.zacks.com/ap/FGEN